The most used therapy for advanced BC (Tamoxifen-resistent-BCs and TNBCs) is based on the use of AR antagonists, such as bicalutamide and enzalutamide, a first and second generation AR antagonist, respectively [(41, 42) and TNBC (47)]. The gene discussed is AR; the disease is breast cancer.